Benefiting from robust growth in the Injectables and Generic segments and an acceleration in sales in Europe and ROW, Hikma reported better than expected results in H2 20. The recently-approved Vascepa’s generic is likely to be a key source of growth in the coming years. Moreover, the upcoming launch of Advair Diskus should bolster growth in the mid-term. Success in cracking one of the most difficult drugs, Advair Diskus, reiterates Hikma’s generic manufacturing prowess.